Click here to close now.

SYS-CON MEDIA Authors: Liz McMillan, Pat Romanski, William Schmarzo, Elizabeth White, tru welu

News Feed Item

Vaccine Industry Watchdog Responds to Forbes' Defense of Mercury-Laced Vaccinations

Dr. Brian Hooker, PhD, says Forbes misrepresented congressional record and CDC studies

CHARLOTTE, N.C., Feb. 28, 2014 /PRNewswire-iReach/ -- Last week, PhD biochemist Brian Hooker created a stir when he announced he had obtained sensitive documents from the CDC (Centers for Disease Control and Prevention) through Freedom of Information Act (FOIA) requests. According to Hooker, these documents implicated the vaccine preservative Thimerosal (50% mercury by weight) in causing autism and other neurodevelopmental disorders, revealing what he says CDC officials had long known, but never disclosed publicly: a 7.6-fold increase in autism during infancy after exposure. Emily Willingham, who frequently editorializes in support of the vaccine program, responded in Forbes by criticizing a news story that went viral on the subject of Dr. Hooker's FOIA revelations.

(Photo: http://photos.prnewswire.com/prnh/20140228/MN73622)

Dr. Hooker methodically itemized "misrepresentations and outright errors" that he says appeared in Forbes.com. "Willingham either confused two CDC studies or intentionally deceived Forbes' readers," said Hooker. "There was one concealed study that found a very high association between Thimerosal and autism. That was the study that was kept from the public which I obtained. And there was a later study by the same researcher – CDC-paid epidemiologist Thomas Verstraeten – who had watered down the results of the earlier study to appear as if there were no association between Thimerosal and autism. That second study was made public even though it was fraudulent.  Willingham pointed to the conclusions of the later study and implied that they came from the earlier study."

Although Willingham denies that the CDC researcher, Dr. Verstraeten, was under pressure to alter the results of the earlier study, Dr. Hooker points out that Verstraeten's own email written at the time (an internal CDC document obtained through FOIA) reveals otherwise. Verstraeten's subject line, "It just won't go away," refers to his difficulty in making the statistical association between Thimerosal and autism disappear.

Making an example of how he says Dr. Verstraeten hid that association in his reanalysis of the data on 400,000 infants, Dr. Hooker says Verstraeten did not include clinics within HMOs where there was a strong correlation between Thimerosal exposure and autism incidence. According to Hooker, "Willingham brazenly disregarded Verstraeten's own chilling words: 'All the harm is done in the first month [of life]…' He wrote those words about the study I obtained."  The abstracts of Verstraeten's two studies and further comment on the controversy can be viewed here.

Dr. Hooker says Willingham misrepresented the congressional record when she selected quotes from a 2007 U.S. Senate report which falsely asserted that allegations of a cover-up are unsubstantiated. He considers the U.S. House of Representatives' 2003 report titled Mercury in Medicine (the result of a 3-year investigation) a "scathing, 80-page indictment of the CDC regarding the Thimerosal coverup."  The report concludes, "Our public health agencies' failure to act is indicative of institutional malfeasance for self-protection and misplaced protectionism of the pharmaceutical industry."

Willingham treated Verstraeten's final, watered-down results as solid epidemiological evidence, when, according to Hooker, the final version of the Verstraeten study is fraught with statistical flaws, primarily "overmatching." He provided an example:  the cases and controls received the same vaccination schedule and the same Thimerosal dosage; thus, no true comparison could be made.  Hooker says this invalidates all of the analyses (done separately for HMOs A, B and C).

Willingham quoted Verstraeten's  2004 letter in the journal Pediatrics regarding his later, diluted study, omitting the fact that the CDC has used the study to exonerate Thimerosal despite Verstraeten calling the study "neutral."  In addition, the 2004 Institute of Medicine (IOM) Immunization Safety Review (ISR) committee report used this as the only U.S. epidemiological study (among the 5 studies) as the basis to reject the Thimerosal-autism hypothesis, shutting the door on any further research. 

"In light of Ms. Willingham's enthusiastic defense of mercury in vaccines despite conclusive evidence of its harm to children, it is ironic that the tagline for her column is 'I write about the science they are selling you.'" remarked Dr. Hooker. Thimerosal is still administered to pregnant women and infants via the flu shot.

Brian Hooker, PhD, PE is an associate professor of biology at Simpson University. His over 50 science and engineering papers have been published in internationally recognized, peer-reviewed journals. He has a son, aged 16, who developed normally but then regressed into autism after receiving Thimerosal-containing vaccines. Dr. Brian Hooker's investigative research is sponsored by the Focus Autism Foundation, which is dedicated to informing the public about the cause(s) of the autism epidemic and the rise of chronic illnesses. To learn more, visit focusautisminc.org and ashotoftruth.org,  an educational website sponsored by Focus Autism. 

AutismOne is co-sponsoring this message and is a non-profit 501(c)(3) organization that provides education and supports advocacy efforts for children and families touched by an autism diagnosis. To learn more, visit autismone.org.

Media Contact: Angela Medlin, A Shot of Truth, 1 866-498-2768, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Brian Hooker, PhD, PE

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session a...
SYS-CON Events announced today that EnterpriseDB (EDB), the leading worldwide provider of enterprise-class Postgres products and database compatibility solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. EDB is the largest provider of Postgres software and services that provides enterprise-class performance and scalability and the open source freedom to divert budget from more costly traditiona...
The multi-trillion economic opportunity around the "Internet of Things" (IoT) is emerging as the hottest topic for investors in 2015. As we connect the physical world with information technology, data from actions, processes and the environment can increase sales, improve efficiencies, automate daily activities and minimize risk. In his session at @ThingsExpo, Ed Maguire, Senior Analyst at CLSA Americas, will describe what is new and different about IoT, explore financial, technological and re...
Andi Mann has been serving as Conference Chair of the DevOps Summit since its inception. He is one of the world's recognized leaders in DevOps, and continues to be one of its most articulate advocates. Here are some recent thoughts of his in an interview we conducted in the run-up to the DevOps Summit to be held June 9-11 at the Javits Center in New York City. When did you first start thinking about DevOps and its potential impact on enterprise IT? Andi: I first started thinking about DevOps b...
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile ...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between confe...
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
The 5th International DevOps Summit, co-located with 17th International Cloud Expo – being held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the...
The web app is Agile. The REST API is Agile. The testing and planning are Agile. But alas, Data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes which force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software orga...
The OpenStack cloud operating system includes Trove, a database abstraction layer. Rather than applications connecting directly to a specific type of database, they connect to Trove, which in turn connects to one or more specific databases. One target database is Postgres Plus Cloud Database, which includes its own RESTful API. Trove was originally developed around MySQL, whose interfaces are significantly less complicated than those of the Postgres cloud database. In his session at 16th Cloud...
There will be 150 billion connected devices by 2020. New digital businesses have already disrupted value chains across every industry. APIs are at the center of the digital business. You need to understand what assets you have that can be exposed digitally, what their digital value chain is, and how to create an effective business model around that value chain to compete in this economy. No enterprise can be complacent and not engage in the digital economy. Learn how to be the disruptor and not ...
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager – Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, will review next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discuss how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Speaker Bios Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has b...
The enterprise market will drive IoT device adoption over the next five years. In his session at @ThingsExpo, John Greenough, an analyst at BI Intelligence, division of Business Insider, will analyze how companies will adopt IoT products and the associated cost of adopting those products. John Greenough is the lead analyst covering the Internet of Things for BI Intelligence- Business Insider’s paid research service. Numerous IoT companies have cited his analysis of the IoT. Prior to joining B...
There is no question that the cloud is where businesses want to host data. Until recently hypervisor virtualization was the most widely used method in cloud computing. Recently virtual containers have been gaining in popularity, and for good reason. In the debate between virtual machines and containers, the latter have been seen as the new kid on the block – and like other emerging technology have had some initial shortcomings. However, the container space has evolved drastically since coming on...